CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.

CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
复制标题

DOI:
10.1016/j.cmet.2017.10.006
复制
发表时间:
2018-01-09
期刊:
影响因子:
29
通讯作者:
Mehrotra S
Mehrotra S
中科院分区:
生物学1区
文献类型:
--
作者:
Chatterjee S;Daenthanasanmak A;Chakraborty P;Wyatt MW;Dhar P;Selvam SP;Fu J;Zhang J;Nguyen H;Kang I;Toth K;Al-Homrani M;Husain M;Beeson G;Ball L;Helke K;Husain S;Garrett-Mayer E;Hardiman G;Mehrotra M;Nishimura MI;Beeson CC;Bupp MG;Wu J;Ogretmen B;Paulos CM;Rathmell J;Yu XZ;Mehrotra S

文献摘要

参考文献

被引文献

相似文献

Th1和Th17细胞的效应功能增强和持续时间延长分别是强效抗肿瘤T细胞的关键特征。在这里,我们建立了离体培养条件,产生了Th1/17杂交细胞,该细胞在体内长期存在,同时保持了其效应功能。利用转录组学和代谢分析方法,我们发现Th1/17细胞抗肿瘤特性的增强依赖于组蛋白去乙酰化酶Sirt1的NAD+依赖性活性的增加。药理或遗传抑制Sirt1活性会损害Th1/17细胞的抗肿瘤潜能。重要的是,NADase CD38表面表达降低的T细胞本质上表现出更高的NAD+,增强的氧化磷酸化,更高的谷氨酰胺水解,以及改变的线粒体动力学,极大地改善了肿瘤控制。最后,即使使用Th0抗肿瘤T细胞,阻断CD38表达也能改善肿瘤控制。因此,靶向CD38-NAD+轴的策略可以提高抗肿瘤过继T细胞治疗的疗效。
Heightened effector function and prolonged persistence, the key attributes of Th1 and Th17 cells, respectively, are key features of potent anti-tumor T cells. Here, we established ex vivo culture conditions to generate hybrid Th1/17 cells, which persisted long-term in vivo while maintaining their effector function. Using transcriptomics and metabolic profiling approaches, we showed that the enhanced anti-tumor property of Th1/17 cells was dependent on the increased NAD+-dependent activity of the histone deacetylase Sirt1. Pharmacological or genetic inhibition of Sirt1 activity impaired the anti-tumor potential of Th1/17 cells. Importantly, T cells with reduced surface expression of the NADase CD38 exhibited intrinsically higher NAD+, enhanced oxidative phosphorylation, higher glutaminolysis, and altered mitochondrial dynamics that vastly improved tumor control. Lastly, blocking CD38 expression improved tumor control even when using Th0 anti-tumor T cells. Thus, strategies targeting the CD38-NAD+ axis could increase the efficacy of anti-tumor adoptive T cell therapy.
DOI: 10.1038/ni.3415
发表时间: 2016-04
期刊: Nature immunology
影响因子: 30.5
作者:
Chang CH;Pearce EL
通讯作者: Pearce EL
DOI: 10.1002/eji.200939427
发表时间: 2009-11
影响因子: 5.4
作者:
Bupp, Melanie R. Gubbels;Edwards, Bonnie;Guo, Caiying;Wei, Datsen;Chen, Gang;Wong, Brian;Masteller, Emma;Peng, Stanford L.
通讯作者: Peng, Stanford L.
DOI: 10.1016/j.cell.2013.05.016
发表时间: 2013-06-06
期刊: Cell
影响因子: 64.5
作者:
Chang CH;Curtis JD;Maggi LB Jr;Faubert B;Villarino AV;O'Sullivan D;Huang SC;van der Windt GJ;Blagih J;Qiu J;Weber JD;Pearce EJ;Jones RG;Pearce EL
通讯作者: Pearce EL
DOI: 10.1196/annals.1320.002
发表时间: 2004-01-01
期刊: CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT
影响因子: --
作者:
Jogl, G;Hsiao, YS;Tong, L
通讯作者: Tong, L
DOI: 10.1016/j.cmet.2016.05.006
发表时间: 2016-06-14
期刊: Cell metabolism
影响因子: 29
作者:
Camacho-Pereira J;Tarragó MG;Chini CCS;Nin V;Escande C;Warner GM;Puranik AS;Schoon RA;Reid JM;Galina A;Chini EN
通讯作者: Chini EN